Insulet Corporation
Insulet Reports Strong Second Quarter 2024 Results and Raises Full Year Guidance
Summary
Insulet Corporation announced financial results for the second quarter of 2024, reporting a 23.2% increase in revenue to $488.5 million, driven by strong demand for its Omnipod 5 product. The company also raised its full-year revenue, gross margin, and operating margin guidance for 2024. Insulet's net income for the quarter was $188.6 million, or $2.59 per diluted share, reflecting a significant increase from the prior year. The company attributed the growth to robust commercial launches of Omnipod 5 in both the U.S. and international markets, and its expansion into the type 2 diabetes market. Adjusted EBITDA for the quarter was $90.8 million, up 310 basis points year-over-year.
Profitelligence Alerts
Get alerts for PODD
Be first to know when Insulet Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Insulet Corporation
Insulet Corporation is a prominent healthcare company specializing in medical devices, with a key focus on diabetes management. Its flagship product, the Omnipod Insulin Management System, is an innovative, tubeless insulin pump that offers users freedom and flexibility, addressing the lifelong needs of individuals with diabetes. The system is acclaimed for its discreet, water-resistant pods, which deliver continuous insulin delivery without the constraints of traditional insulin pumps. Insulet Corporation plays a crucial role in the medical technology industry by enhancing patient experiences and outcomes. Headquartered in Acton, Massachusetts, Insulet Corporation continues to pioneer advancements in insulin delivery solutions, directly impacting healthcare providers and improving the quality of life for diabetes patients globally. Its market significance is underscored by its commitment to innovation and accessibility, bridging the gap between technology and patient-centric care in the rapidly evolving healthcare sector.
Official SEC Documents
Advertisement